Certified Centre News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Four-year progression-free survival outcomes revealed the BrECADD regimen was superior to the eBEACOPP regimen, and BrECADD had a promising benefit-risk profile.

Peter borchmannDepartment of haematologyCertified centre for haematological malignanciesGerman hodgkin study groupUniversity hospital of cologneCertified centreHaematological malignanciesUniversity hospital